Madrigal Pharmaceuticals Inc
MDGL
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.33B
Close$
$1185.22
120% upside
Current Fair Value
120% upsideUndervalued by 120% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.33 Billion |
|---|---|
| Enterprise Value | $12.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.85 |
| Beta | -1 |
| Outstanding Shares | 29,145,271 |
Return
| Return on Equity | -62.07% |
|---|---|
| Return on Assets | -26.12% |
| Return on Invested Capital | -39.96% |
Valuation & Multiples
| P/E Ratio | -41.41 |
|---|---|
| PEG | -111.82 |
| Price to Sales | 12.24 |
| Price to Book Ratio | 31.69 |
| Enterprise Value to Revenue | 9.65 |
| Enterprise Value to EBIT | -35.62 |
| Enterprise Value to Net Income | -39 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-2.66
Average shareholder expectationRevenue Estimate
$350.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$404.17 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6336▲ 9.66% |
|---|---|
| Total Calls | 702,300▲ 9.84% |
| Total Puts | 445,000▲ 29.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 113.63%▲ 7.66% |
|---|---|
| Total Invested | $12.77B▲ 2.60% |
| Investors Holding | 437▲ 30.00% |
ESG Score
No data
About Madrigal Pharmaceuticals Inc
CEO: Rebecca Taub